MedTrace Logo

Embolism in COVID-19 Positive Patients

NCT04910360 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-02-15

No results posted yet for this study

Summary

Covid-19 outbreak has caused death of millions of people because of not only the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection itself but also infection dependent complications. Abnormalities in thrombotic events leads to some of these complications which eventually result in emboli. The endothelial damage caused by the virus interacting with ACE2 on the host cells leads to the activation of coagulation cascade. Accumulation of byproducts of the cascade might have some roles in embolism inducing risk of organ damage, other life-threatening problems, and even death. To enlighten the factors triggering embolism, the investigators have focused on genetic changes such as polymorphisms and mutations in certain genes in DNA samples coming from intensive care unit (ICU) patients.

Conditions

Sponsors & Collaborators

  • Afyonkarahisar Health Sciences University

    lead OTHER

Principal Investigators

  • Serdar Ceylaner, Assoc. Prof. · INTERGEN Genetics and Rare Diseases Diagnosis Research & Application Center

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-05
Primary Completion
2021-05-08
Completion
2022-08-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04910360 on ClinicalTrials.gov